Last updated on February 2019

A Randomized Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis

Brief description of study

PHASE : IV TYPE OF STUDY : With direct benefit. DESCRIPTIVE : Multicentre, randomized, open label study. INCLUSION CRITERIA : Acute severe ulcerative colitis. OBJECTIVES : To compare the efficacy and safety of early administration of the combination therapy with infliximab and azathioprine with steroids and azathioprine in patients with acute severe ulcerative colitis treated with intravenous steroids.

STUDY TREATMENTS : All patients :

Intravenous steroids (0.8 mg/kg/day of methylprednisolone or equivalent) for 5 days.

Combination therapy arm:

Infliximab 5 mg/kg plus Azathioprine 2-2.5 mg/kg/day.

Azathioprine arm:

Steroids tapering for 3 months and Azathioprine 2-2.5 mg/kg/day.

Detailed Study Description

NUMBER OF PATIENTS : 75 patients in each group i.e. a total of 150 patients. RECRUITMENT PERIOD : 24 months STUDY DURATION : 36 months

PRIMARY END POINT : Treatment failure is defined by:

  • Absence of steroid-free remission at W52 according to the total Mayo Disease Activity Index score
  • OR Absence of mucosal healing (Mayo endoscopic subscore 0-1)
  • OR Adverse event leading to treatment interruption
  • OR Colectomy
  • OR Death
  • OR Infliximab withdrawal in the combination therapy group OR Infliximab introduction in the azathioprine group SECONDARY END POINT: - Clinical response and remission at D7, W14 and W52 (according to Lichtiger score and total Mayo Disease Activity Index score)
  • Endoscopic and histological response
  • Mucosal healing (partial endoscopic Mayo subscore 0)
  • Colectomy rate
  • Adverse events rate
  • Fecal calprotectin
  • Health-economic outcome

Clinical Study Identifier: NCT02425852

Find a site near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.